Evogene Ltd. (NASDAQ:EVGN) Q3 2024 Earnings Conference Call November 21, 2024 9:00 AM ET
Company Participants
Ofer Haviv - President and CEO
Yaron Eldad - CFO
Amit Noam - CEO, Lavie BIO
Operator
Welcome to Evogene's Third Quarter Results Conference Call. [Operator Instructions] All participants are present in listen only mode. Following management's formal presentation, we will open the question-and-answer session. [Operator Instructions]
As a reminder, this conference is being recorded November 21, 2024. This presentation contains forward-looking statements relating to future events and Evogene LTD may, from time to time, make other statements regarding our outlook or expectations of future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995 and other securities laws as amended.
Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should planned, estimated, intend and potential or words of similar meaning. We are using forward-looking statements in this presentation when we discuss Evogene's strategy and vision.
Evogene's value proposition and ability to identify and optimize candidates enhance the likelihood of achieving breakthrough products within competitive time lines and in a cost-effective way, Evogene's partnerships and Evogene's ability to harness value and leverage ChemPass AI, the expected timing of and ability of Casterra to supply purchase orders, the expected timing of Lavie Bio sale, AgPlenus Pipeline by Biomica’s BMC128 future activity and Evogene's projected cash usage for 2024 and Evogene anticipated continued revenue growth in for 2024.
Such statements are based on current expectations estimates, projections and assumptions described opinions about future events, involve certain risks and uncertainties which are difficult to predict, and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.
Therefore, actual future results, performance or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors. Many of which are beyond our control, including without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel, such as further mobilization or escalation in the northern border of Israel, those described in greater detail on Evogene's Annual Report on Form 20-F and in other information, Evogene files and furnishes with the Israel Securities Authority and the US Securities and Exchange Commission, including those factors under the heading Risk Factors.